Let's capitalize on analyst incompetence—and bank yields up to 18.3%, with upside to boot!

Stock News Discount chains gain share: Budget-conscious consumers are flocking to discounters, with Aldi adding 17 million U.S. customers in 2025 and planning 1

ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continued good execution,” including a February financing and the addition of Jeff Knight as chief development and chief operating officer.

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.6 per share, missing the Zacks Consensus Estimate of $3.08 per share. This compares to FFO of $4.06 per share a year ago.

On May 01, 2026, Alexander's Inc (ALX) shares fell 3.0%, closing at $244.34. The stock has traded within a 52-week range of $201.28 to $260.84, reflecting some

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company's investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatamab (ZIIHERA®) in heavily pretreated patients with HER2-positive metastatic breast cancer (mBC) will be presented at the ESMO Breast Cancer 2026 Congress in Berlin on May 7.

PARAMUS, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on May 29, 2026 to stockholders of record on May 11, 2026.

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended March 31, 2026 with the U.S. Securities and Exchange Commission and issue its first quarter earnings release on Monday, May  4, 2026, before the New York Stock Exchange opens.